Huntington National Bank’s SpringWorks Therapeutics SWTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$47 Hold
1
﹤0.01% 2946
2025
Q4
$47 Hold
1
﹤0.01% 2864
2025
Q3
$47 Sell
1
-442
-100% -$20.8K ﹤0.01% 2933
2025
Q2
$20.8K Buy
443
+16
+4% +$712 ﹤0.01% 1556
2025
Q1
$18.8K Sell
427
-267
-38% -$12.3K ﹤0.01% 1539
2024
Q4
$25.1K Buy
694
+192
+38% +$6.71K ﹤0.01% 1473
2024
Q3
$16.1K Sell
502
-10
-2% -$374 ﹤0.01% 1584
2024
Q2
$19.3K Buy
+512
New +$21.6K ﹤0.01% 1469

Huntington National Bank's SWTX Position: Q1 2026 in Review

Huntington National Bank held its SpringWorks Therapeutics (SWTX) position steady in Q1 2026 at 1 share worth $47. The position accounts for ﹤0.01% of the portfolio, ranked #2946.

Huntington National Bank first reported a position in SWTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $25.1K in Q4 2024. 1 fund tracked by Wall St. Rank holds SWTX as of Q1 2026.

  • Huntington National Bank held 1 share of SpringWorks Therapeutics worth $47 as of Q1 2026.
  • Huntington National Bank left its SpringWorks Therapeutics share count unchanged in Q1 2026.
  • SpringWorks Therapeutics made up ﹤0.01% of Huntington National Bank's portfolio in Q1 2026, its #2946 holding.
  • Huntington National Bank first reported a position in SpringWorks Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Huntington National Bank's SpringWorks Therapeutics position peaked at $25.1K in Q4 2024.
  • 1 fund tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2026.

Based on Huntington National Bank's 13F filing for Q1 2026, filed 15 May 2026.